AbbVie's Humira gets a U.S. rival, but costs could stay high

<html xmlns=""><head><title>FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high</title></head><body>

Updates to clarify lower price may not be widely used, rather than widely available, and why

By Patrick Wingrove

Jan 31 (Reuters) -U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.

Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.

One sets a 5% discount to Humira’s monthly price of $6,922. The other will be about half price but may not be widely used as it is unlikely to appeal to pharmacy benefit managers (PBMs)that recommend which drugs most insurance providers should cover.

Most patients’ co-insurance costs are set as a percentage of list price and are expected to be calculated off the higher price.

At least another seven Humira biosimilars are expected this summer and could debut with discounted list prices. Even then, patient groups, pharmacists, doctors and academics said they will be obscured by the U.S. private insurance system of middlemen negotiation and after-market discounts called rebates.

PBMs saythat the deep discounts they receive are returned to insurers and employers to lower their overall medical costs.

Benjamin Rome, a drug pricing researcher at Harvard Medical School, said introduction of biosimilars in the United States has not sent prices tumbling as originally expected.

Unlike pills, which have extremely cheap generic copies, complex, expensive biologic drugs made from living cells cannot be exactly duplicated. Their closest alternatives are called biosimilars.

"The bottom line is it’s feasible that even if prices for Humira and biosimilars go down, this could be in the form of higher rebates to PBMs rather than actual lower prices that are passed onto patients," Rome said.

The U.S. pays the highest drug prices in the world, in part because many different private sector companies do not have the power of a single government payer.

The Biden Administration’s Inflation Reduction Act will allow the government’s Medicare program for people aged 65 and older to negotiate prices of its most costly medicines, but drugs like Humira with direct competition are excluded.

Humira - the world's biggest selling non-COVID prescription drug - is used to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis.

A 5% lower list price would result in a savings of about $35 a month for a person whose coinsurance payment is 10% of the list price.

Some patients who qualify for AbbVie’s patient assistance programs pay heavily discounted rates. Amgen has launched a similar savings program for its version.

There are currently about half a dozen drugs with biosimilar competition in the United States. Prices of those have decreased up to 20%, according to a report from the National Bureau of Economic Research.

Amgen has set list prices of $1,557 and $3,288 per 40 milligram pen device, a two-week supply. Amgen executive Murdo Gordon told Reuters the lower price would attract healthcare systems that act as both an insurer and a provider and typically do not seek after-market discounts.

"If you think of a pharmaceutical benefit manager, they would prefer the high list price, because their business model is extracting rebates from manufacturers and passing them on to their employer, customers or their downstream health plan customers," Gordon said.

UnitedHealth Group’s UNH.N OptumRX and Cigna Corp CI.N said last year they had deals to make Humira, as well as rivals from Amgen and others, available under the same pricing and access terms. CVS Health CVS.N, another large PBM, plans to include the drug on its coverage list but as non-preferred with less favorable terms.

JC Scott, president of the Pharmaceutical Care Management Association, said PBMs want more competition in the prescription drug marketplace and discouraged delays sought by drugmakers.

"The bottom line is that increased competition is the most effective and sustainable way to drive prescription drug costs down," he said.


In Europe, where governments negotiate drug prices, AbbVie offered up to 80% discounts in November 2018, a month after Humira went off patent, Reuters reported.

Additional AbbVie patents continued to protect it in the United States, and the company struck deals with Amgen and others to allow rival drugs in exchange for royalty payments.

AbbVie declined to comment.

Douglas Hoey, chief executive of the National Community Pharmacists Association, said he expected U.S. prices for drugs of this type to fall about 15%-20% after new competition enters in July.

But Robert Popovian, the chief science policy officer at patient advocacy group Global Healthy Living Foundation, said it would take further market and public pressure after the summer entries to get list prices down.

Analysts expect the introduction of biosimilar competition will drive down Humira sales. They are forecasting sales of $21.2 billion in 2022, dropping to $13.4 billion this year and $8.3 billion in 2024, according to Refinitiv. Analysts expect Amgen’s biosimilar to garner sales of $747.6 million in 2023 and $933.8 million in 2024.

Marcus Snow, a rheumatologist at the University of Nebraska Medical Center, said he would prescribe adalimumab, the chemical name for Humira, based on price and each patient’s insurance coverage terms.

All things being equal, he said, he would keep existing patients on Humira and try to put new patients on the medicine that was most likely to be given preference on formularies in the future, to avoid switching.

"I wouldn't expect to see the price changes that we all hope to have in the first year," Snow said.

GRAPHIC-More U.S. competition ahead for AbbVie's Humira

Reporting by Patrick Wingrove in New York; Editing by Caroline Humer and Bill Berkrot


면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

우리는 웹사이트에서 최고의 경험을 전해드리기 위해 쿠키를 사용하고 있습니다. 자세히 읽거나 쿠키 설정을 변경하세요.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.